MX2017007059A - Polipéptidos que comprenden una secuencia de aminoácidos modificada de bacteriófago g3p, que carece de señal de glicosilación. - Google Patents
Polipéptidos que comprenden una secuencia de aminoácidos modificada de bacteriófago g3p, que carece de señal de glicosilación.Info
- Publication number
- MX2017007059A MX2017007059A MX2017007059A MX2017007059A MX2017007059A MX 2017007059 A MX2017007059 A MX 2017007059A MX 2017007059 A MX2017007059 A MX 2017007059A MX 2017007059 A MX2017007059 A MX 2017007059A MX 2017007059 A MX2017007059 A MX 2017007059A
- Authority
- MX
- Mexico
- Prior art keywords
- polypeptides
- amino acid
- acid sequence
- modified
- sequence lacking
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 241001515965 unidentified phage Species 0.000 title 1
- 238000006467 substitution reaction Methods 0.000 abstract 2
- 101710192393 Attachment protein G3P Proteins 0.000 abstract 1
- 241000724791 Filamentous phage Species 0.000 abstract 1
- 101710179596 Gene 3 protein Proteins 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 238000004220 aggregation Methods 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000013595 glycosylation Effects 0.000 abstract 1
- 238000006206 glycosylation reaction Methods 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000037431 insertion Effects 0.000 abstract 1
- 238000003780 insertion Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1716—Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/14011—Details ssDNA Bacteriophages
- C12N2795/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462087052P | 2014-12-03 | 2014-12-03 | |
| PCT/US2015/063476 WO2016090022A1 (en) | 2014-12-03 | 2015-12-02 | Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a gylcosylation signal |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017007059A true MX2017007059A (es) | 2018-05-02 |
Family
ID=55273507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017007059A MX2017007059A (es) | 2014-12-03 | 2015-12-02 | Polipéptidos que comprenden una secuencia de aminoácidos modificada de bacteriófago g3p, que carece de señal de glicosilación. |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10722551B2 (enExample) |
| EP (1) | EP3227313B1 (enExample) |
| JP (2) | JP6730988B2 (enExample) |
| KR (1) | KR20170085132A (enExample) |
| CN (1) | CN107250154A (enExample) |
| AR (1) | AR102890A1 (enExample) |
| AU (1) | AU2015358504A1 (enExample) |
| BR (1) | BR112017011530A2 (enExample) |
| CA (1) | CA2969128A1 (enExample) |
| DK (1) | DK3227313T3 (enExample) |
| EA (1) | EA201791212A1 (enExample) |
| ES (1) | ES2910017T3 (enExample) |
| IL (1) | IL252426A0 (enExample) |
| MX (1) | MX2017007059A (enExample) |
| PH (1) | PH12017501004A1 (enExample) |
| PL (1) | PL3227313T3 (enExample) |
| PT (1) | PT3227313T (enExample) |
| SG (1) | SG11201704427YA (enExample) |
| TW (1) | TW201632542A (enExample) |
| WO (1) | WO2016090022A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9493515B2 (en) | 2011-11-29 | 2016-11-15 | Proclara Biosciences, Inc. | Bacteriophage gene 3 protein compositions and use as amyloid binding agents |
| EA033666B1 (ru) | 2012-10-02 | 2019-11-14 | Proclara Biosciences Inc | Амилоидсвязывающие белки и их применение |
| JP2016526044A (ja) | 2013-05-28 | 2016-09-01 | ニューロファージ ファーマシューティカルズ， インコーポレイテッド | 低減された免疫原性を有する修飾されたバクテリオファージｇ３ｐアミノ酸配列を含むポリペプチド |
| KR20170085132A (ko) | 2014-12-03 | 2017-07-21 | 프로클라라 바이오사이언시즈, 인크. | 글리코실화 신호가 결핍된 변형된 박테리오파지 ｇ3ｐ 아미노산 서열을 포함하는 폴리펩티드 |
| EP3806884B1 (en) | 2018-06-15 | 2023-08-02 | Amyl Therapeutics | General amyloid interaction motif (gaim) |
| CN120641092A (zh) | 2022-12-02 | 2025-09-12 | 阿尔泽恩股份有限公司 | 用于用曲米沙特治疗神经变性病症的方法 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3941763A (en) | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
| US4215051A (en) | 1979-08-29 | 1980-07-29 | Standard Oil Company (Indiana) | Formation, purification and recovery of phthalic anhydride |
| DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
| EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| DE59010908D1 (de) | 1989-09-12 | 2000-08-10 | Hoffmann La Roche | TNF-bindende Proteine |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| AU1674292A (en) | 1991-03-15 | 1992-10-21 | Synergen, Inc. | Pegylation of polypeptides |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| ATE311895T1 (de) | 1992-05-26 | 2005-12-15 | Immunex Corp | Neue zytokine die cd30 binden |
| EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
| AU776910B2 (en) | 1998-12-08 | 2004-09-23 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Modifying protein immunogenicity |
| US20020052311A1 (en) | 1999-09-03 | 2002-05-02 | Beka Solomon | Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders |
| US8022270B2 (en) | 2000-07-31 | 2011-09-20 | Biolex Therapeutics, Inc. | Expression of biologically active polypeptides in duckweed |
| PL362324A1 (en) | 2001-02-19 | 2004-10-18 | Merck Patent Gmbh | Artificial fusion proteins with reduced immunogenicity |
| WO2002070548A2 (en) | 2001-03-08 | 2002-09-12 | Merck Patent Gmbh | Modified human granulocyte macrophage colony stimulating factor (gm-csf) with reduced immunogenicity |
| DE10238846A1 (de) | 2002-08-20 | 2004-03-04 | Nemod Immuntherapie Ag | Aktive Fusionsproteine und Verfahren zu ihrer Herstellung |
| JP5096169B2 (ja) | 2005-02-01 | 2012-12-12 | ラモット・アット・テルアビブ・ユニバーシティ | アミロイド沈着に付随する炎症および活性化されたマイクログリアにかかわる脳の炎症の処置法 |
| MX2008010612A (es) | 2006-02-15 | 2009-03-20 | Ramot At Tel Aviv University | Bacteriofago filamentoso que exhibe proteina a como aglutinante de anticuerpos e inmunocomplejos para el suministro hacia el cerebro. |
| US20090304726A1 (en) | 2006-02-15 | 2009-12-10 | Ramot At Tel Aviv University Ltd. | Viral display vehicles for treating multiple sclerosis |
| WO2007109733A2 (en) | 2006-03-21 | 2007-09-27 | The Johns Hopkins University | Diagnostic and prognostic markers and treatment strategies for multiple sclerosis |
| JPWO2007114139A1 (ja) | 2006-04-06 | 2009-08-13 | 文昭 内山 | 新規繊維状ファージによるファージディスプレイ |
| US20090324554A1 (en) | 2006-07-21 | 2009-12-31 | Ramot At Tel Aviv University Ltd. | Method for inhibiting or treating a disease associated with intracellular formation of protein fibrillar or aggregates |
| KR101485202B1 (ko) | 2006-10-11 | 2015-01-22 | 안티토페 리미티드 | Ｔ 세포 에피토프 데이터베이스들 |
| US20110182948A1 (en) | 2008-05-22 | 2011-07-28 | Beka Solomon | Method for treating disease characterized by plaque |
| AU2009316326A1 (en) | 2008-11-24 | 2010-05-27 | Ramot At Tel-Aviv University Ltd. | Method for treating Parkinson' s disease using filamentous bacteriophage |
| WO2011084714A2 (en) | 2009-12-17 | 2011-07-14 | Biogen Idec Ma Inc. | STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF |
| BR112013023040A2 (pt) | 2011-03-11 | 2018-10-23 | Univ Ramot | bacteriófago filamentoso, composição farmacêutica, e, métodos para reduzir a formação de fibrilas de proteína tau ou para desagregar fibrilas pré-formadas de proteína tau em um paciente, e para tratar uma tauopatia degenerativa. |
| US9493515B2 (en) * | 2011-11-29 | 2016-11-15 | Proclara Biosciences, Inc. | Bacteriophage gene 3 protein compositions and use as amyloid binding agents |
| EA033666B1 (ru) * | 2012-10-02 | 2019-11-14 | Proclara Biosciences Inc | Амилоидсвязывающие белки и их применение |
| JP2016526044A (ja) * | 2013-05-28 | 2016-09-01 | ニューロファージ ファーマシューティカルズ， インコーポレイテッド | 低減された免疫原性を有する修飾されたバクテリオファージｇ３ｐアミノ酸配列を含むポリペプチド |
| KR20170085132A (ko) | 2014-12-03 | 2017-07-21 | 프로클라라 바이오사이언시즈, 인크. | 글리코실화 신호가 결핍된 변형된 박테리오파지 ｇ3ｐ 아미노산 서열을 포함하는 폴리펩티드 |
-
2015
- 2015-12-02 KR KR1020177017763A patent/KR20170085132A/ko not_active Withdrawn
- 2015-12-02 DK DK15831011.0T patent/DK3227313T3/da active
- 2015-12-02 ES ES15831011T patent/ES2910017T3/es active Active
- 2015-12-02 SG SG11201704427YA patent/SG11201704427YA/en unknown
- 2015-12-02 AU AU2015358504A patent/AU2015358504A1/en not_active Abandoned
- 2015-12-02 US US15/532,820 patent/US10722551B2/en active Active
- 2015-12-02 JP JP2017529043A patent/JP6730988B2/ja not_active Expired - Fee Related
- 2015-12-02 BR BR112017011530A patent/BR112017011530A2/pt not_active Application Discontinuation
- 2015-12-02 WO PCT/US2015/063476 patent/WO2016090022A1/en not_active Ceased
- 2015-12-02 PL PL15831011T patent/PL3227313T3/pl unknown
- 2015-12-02 EP EP15831011.0A patent/EP3227313B1/en active Active
- 2015-12-02 CN CN201580065696.9A patent/CN107250154A/zh active Pending
- 2015-12-02 MX MX2017007059A patent/MX2017007059A/es unknown
- 2015-12-02 TW TW104140347A patent/TW201632542A/zh unknown
- 2015-12-02 EA EA201791212A patent/EA201791212A1/ru unknown
- 2015-12-02 PT PT158310110T patent/PT3227313T/pt unknown
- 2015-12-02 CA CA2969128A patent/CA2969128A1/en not_active Abandoned
- 2015-12-03 AR ARP150103956A patent/AR102890A1/es unknown
-
2017
- 2017-05-22 IL IL252426A patent/IL252426A0/en unknown
- 2017-05-31 PH PH12017501004A patent/PH12017501004A1/en unknown
-
2020
- 2020-02-19 JP JP2020026300A patent/JP2020073610A/ja not_active Withdrawn
- 2020-06-18 US US16/905,128 patent/US11723951B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PH12017501004A1 (en) | 2017-12-18 |
| US10722551B2 (en) | 2020-07-28 |
| SG11201704427YA (en) | 2017-06-29 |
| US20180207231A1 (en) | 2018-07-26 |
| WO2016090022A9 (en) | 2016-08-25 |
| DK3227313T3 (da) | 2022-04-19 |
| BR112017011530A2 (pt) | 2018-03-13 |
| CN107250154A (zh) | 2017-10-13 |
| AU2015358504A8 (en) | 2017-07-13 |
| PT3227313T (pt) | 2022-04-12 |
| EA201791212A1 (ru) | 2018-01-31 |
| EP3227313B1 (en) | 2022-02-09 |
| JP6730988B2 (ja) | 2020-07-29 |
| IL252426A0 (en) | 2017-07-31 |
| WO2016090022A1 (en) | 2016-06-09 |
| WO2016090022A8 (en) | 2017-06-22 |
| EP3227313A1 (en) | 2017-10-11 |
| AR102890A1 (es) | 2017-03-29 |
| PL3227313T3 (pl) | 2022-05-09 |
| CA2969128A1 (en) | 2016-06-09 |
| KR20170085132A (ko) | 2017-07-21 |
| TW201632542A (zh) | 2016-09-16 |
| JP2020073610A (ja) | 2020-05-14 |
| AU2015358504A1 (en) | 2017-06-29 |
| ES2910017T3 (es) | 2022-05-11 |
| JP2017538407A (ja) | 2017-12-28 |
| US20210015895A1 (en) | 2021-01-21 |
| US11723951B2 (en) | 2023-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015502585A1 (en) | Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity | |
| PH12017501004A1 (en) | Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a glycosylation signal | |
| MX2022005291A (es) | Vacunas para el tratamiento y prevencion del cancer. | |
| MY196882A (en) | Recombinant binding proteins and their use | |
| PH12017500834A1 (en) | Methods and formulations for treating vascular eye diseases | |
| PH12018500477A1 (en) | Recombinant vectors comprising 2a peptide | |
| MX2021006017A (es) | Polipeptidos de folistatina y sus usos. | |
| PH12017500032B1 (en) | Improved aã protofibril binding antibodies | |
| WO2015048348A3 (en) | Compositions and formulations for increasing renal function and treatment and prevention of renal diseases, and methods of production and use thereof | |
| MX359953B (es) | Ácido nucleico que comprende o que codifica un tallo-rizo de histona y una secuencia poli (a) o una señal de poliadenilación para incrementar la expresión de una proteína terapéutica codificada. | |
| WO2014204816A3 (en) | Method for assessing protein identity and stability | |
| NZ721015A (en) | Mutant fragments of ospa and methods and uses relating thereto | |
| WO2018053029A8 (en) | Methods for treating pulmonary disease using inter-alpha inhibitor proteins | |
| HK1258125A1 (zh) | 胰岛素免疫球蛋白融合蛋白 | |
| MX2016011517A (es) | Peptidos de crmp2 no narcoticos que seleccionan como diana canales de sodio para el dolor cronico. | |
| MY205028A (en) | Protein for treatment of inflammatory diseases | |
| MX2019003970A (es) | Péptidos de arginasa inmunogénicos. | |
| WO2015168488A3 (en) | Islet amyloid polypeptides with improved solubility | |
| WO2013006050A9 (en) | Peptides inducing or enhancing an immune response against prostate-specific membrane protein (psma) | |
| MX394834B (es) | Proteína de fusión para usarse en el tratamiento/prevención de una infección por virus de hepatitis b. | |
| IN2014CN00510A (enExample) | ||
| NZ728041A (en) | Substances and methods for the use in prevention and/or treatment in huntington’s disease | |
| ZA202201468B (en) | Method | |
| MX358118B (es) | Vacuna contra el virus de la leucemia bovina. | |
| PH12016501608A1 (en) | Peptides and methods of use |